New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 19, 2012
13:24 EDTCAH, ABC, MCK, GSKGlaxoSmithKline settles nasal spray litigation for $150M, Reuters reports
GlaxoSmithKline Plc (GSK) has reached a preliminary $150M settlement with U.S. drug wholesalers regarding generic nasal spray litigation, according to Reuters. Reference Link
News For GSK;ABC;CAH;MCK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 26, 2014
17:16 EDTGSKGSK says Ebola candidate vaccine well-tolerated, gets immunological response
Subscribe for More Information
14:38 EDTGSKNovartis to divest Habitrol nicotine patch to settle FTC charges over Glaxo jv
Subscribe for More Information
10:34 EDTGSKMylan advances after called 'most likely' Pfizer takeover target
Subscribe for More Information
07:48 EDTGSKMylan now most likely takeover target for Pfizer, says Jefferies
Jefferies believes Mylan (MYL), following its combination with Abbott's (ABT) Developed Markets Established Products business, is now the most likely takeover target of Pfizer (PFE). The firm thinks Pfizer management is highly motivated to either merge with, invert into or acquire a foreign company. It believes Actavis (ACT) and AstraZeneca (AZN) are off the table as potential Pfizer targets given the former's takeover of Allergan (AGN) and latter's oncology deal with Merck KGaA (MKGAY). Jefferies calls GlaxoSmithKline (GSK) the "wild card" potential takeover target for Pfizer. The firm estimates Pfizer could pay a 25% premium for Mylan and have the deal be highly accretive.
November 25, 2014
10:00 EDTGSKOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 3M Company (MMM) initiated with an Underperform at RBC Capital... Ametek (AME) initiated with an Outperform at RBC Capital... AstraZeneca (AZN) initiated with an Outperform at Exane BNP Paribas... Bayer (BAYRY) initiated with a Neutral at Exane BNP Paribas... Carlisle (CSL) initiated with a Sector Perform at RBC Capital... Colfax (CFX) initiated with a Sector Perform at RBC Capital... Dover (DOV) initiated with a Sector Perform at RBC Capital... Eaton (ETN) initiated with a Sector Perform at RBC Capital... Emerson (EMR) initiated with a Sector Perform at RBC Capital... Evercore Partners (EVR) initiated with an Outperform at Macquarie... Fifth Street Asset (FSAM) initiated with a Buy at MLV & Co.... Flowserve (FLS) initiated with an Underperform at RBC Capital... General Electric (GE) initiated with an Outperform at RBC Capital... GlaxoSmithKline (GSK) initiated with an Underperform at Exane BNP Paribas... Grainger (GWW) initiated with a Sector Perform at RBC Capital... Hanesbrands (HBI) initiated with a Buy at UBS... Hercules Technology (HTGC) initiated with a Neutral at Macquarie... HomeStreet (HMST) initiated with a Neutral at Macquarie... Honeywell (HON) initiated with an Outperform at RBC Capital... IDEX Corp. (IEX) initiated with an Outperform at RBC Capital... Illinois Tool Works (ITW) initiated with a Sector Perform at RBC Capital... Ingersoll-Rand (IR) initiated with a Sector Perform at RBC Capital... ManTech (MANT) initiated with a Buy at Maxim... Novartis (NVS) initiated with an Outperform at Exane BNP Paribas... Nu Skin (NUS) initiated with a Neutral at Citigroup... Oppenheimer Holdings (OPY) initiated with a Neutral at Macquarie... Pentair (PNR) initiated with an Outperform at RBC Capital... Raymond James (RJF) initiated with a Neutral at Macquarie... Roche (RHHBY) initiated with an Outperform at Exane BNP Paribas... Roper Industries (ROP) initiated with an Outperform at RBC Capital... SPX Corp. (SPW) initiated with a Sector Perform at RBC Capital... Sanofi (SNY) initiated with an Outperform at Exane BNP Paribas... Tyco (TYC) initiated with an Outperform at RBC Capital... United Technologies (UTX) initiated with an Outperform at RBC Capital... WESCO (WCC) initiated with an Outperform at RBC Capital... Xylem (XYL) initiated with a Sector Perform at RBC Capital.
05:26 EDTGSKGlaxoSmithKline initiated with an Underperform at Exane BNP Paribas
Subscribe for More Information
November 24, 2014
08:31 EDTMCKOmnicare, McKesson expand distribution agreement
Omnicare (OCR) and McKesson Corporation (MCK) announced the signing of an expanded agreement to include the sourcing and distribution of branded, specialty and generic pharmaceuticals. The new five year agreement, which extends through December 2019, creates efficiencies for both companies by leveraging the strength of Omnicare as the nation’s largest institutional pharmacy and a leading specialty pharmaceutical services provider and McKesson as a global leader in pharmaceutical sourcing and supply chain management. Omnicare noted that it believes the benefits of its new sourcing strategy will be a key driver in enabling it to generate a low double-digit adjusted cash EPS growth rate in 2015.
07:33 EDTMCKBrean Capital to hold a summit
Subscribe for More Information
07:31 EDTGSKMerck, NewLink Genetics enter into agreement for investigational Ebola vaccine
Subscribe for More Information
06:32 EDTGSKGSK investors expected to vote on Novartis deal in December, Reuters reports
Subscribe for More Information
November 21, 2014
10:00 EDTABCOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:32 EDTABCAmerisourceBergen downgraded to Market Perform at FBR Capital
FBR Capital downgraded AmerisourceBergen to Market Perform from Outperform saying the stock's valuation reflects the company's long-term growth prospects. FBR keeps a $90 price target on shares.
07:08 EDTCAHHenry Schein, Cardinal Health Enter long-term strategic agreement
Cardinal Health (CAH) and Henry Schein (HSIC) announced that the companies have entered into a long-term strategic agreement to provide one of the most comprehensive service and product offerings to office-based medical practices. This strategic agreement combines Cardinal Health's product line and extensive touch points across the health system with Henry Schein's outstanding service capabilities and history in serving office-based practices. Under the terms of the agreement, the physician office-focused commercial organization of Cardinal Health's Medical segment will be consolidated into the commercial organization of Henry Schein's Medical Group. Henry Schein has committed to purchase Cardinal Health Brand products and utilize Cardinal Health as a primary source for various medical products.
06:15 EDTABCAmerisourceBergen downgraded to Market Perform from Outperform at FBR Capital
Subscribe for More Information
November 19, 2014
07:52 EDTGSKInforma Business Information to hold a conference
Subscribe for More Information
November 18, 2014
07:20 EDTGSKEuro Organization for Research & Treatment of Cancer co-hosts a symposium
Subscribe for More Information
November 17, 2014
17:02 EDTGSKClovis in oncology clinical trial collaboration with GlaxoSmithKline
Subscribe for More Information
08:37 EDTCAHCardinal Health management to meet with FBR Capital
Meetings to be held in the Midwest November 17-18 hosted by FBR Capital.
07:00 EDTMCKNovaBay signs distribution agreement with McKesson
NovaBay (NBY) has signed a nationwide distribution agreement with McKesson Corporation (MCK). The agreement covers NovaBay’s i-LidTM Cleanser, a prescription lid and lash hygiene product for the management of debilitating eye conditions such as blepharitis, Meibomian gland dysfunction and associated dry eye.
05:32 EDTGSKMedidata announces collaboration with GlaxoSmithKline
Medidata (MDSO) announced the completion of a method development project conducted in partnership with GlaxoSmithKline (GSK) to evaluate the impact of unifying mobile health, or mHealth, devices with cloud-based technologies in a clinical trial setting. The joint initiative assessed the capabilities of mHealth tools and evaluated how they could be used to enable a new model for clinical trial conduct that aligns site and patient needs with faster study execution and reduced costs. The collaborative project, which took place at GSK’s Human Performance Lab, demonstrated that mHealth technologies have the power to comprehensively collect large volumes of objective data that is reliable, secure and analysis-ready, and provides real-time, continuous insight into the well being of patients. All of the data collected was audited and is compliant with FDA regulations. Additionally, the effort indicated that mobile devices can support the long-term goal of lessening the burden on patients participating in studies by streamlining routine procedures, eliminating unnecessary ones and reducing visits to clinical trial sites.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use